Acasti Pharma Announces Change to Board of Directors

Acasti Pharma (NASDAQ:ACST) announced Neptune’s representatives, Rick Schottenfeld and Katherine Crewe, have resigned from Acasti’s Board of Directors.
As quoted from the press release:

Acasti will immediately begin the process of recruiting new directors and expects to regain compliance with Nasdaq Listing Rule 5605 and National Instrument 52-110 of the Canadian securities regulators, which require a company’s audit committee to be comprised of at least three independent directors, within six months and in any event prior to Acasti’s next annual shareholders’ meeting.

Click here to read the full press release.